Article in Clinical journal of the American Society of Nephrology : CJASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Armin AhmadiDivision of Nephrology, Department of Internal Medicine, University of California, Davis, California.ORCID 0000-0002-7711-2356
Jorge GamboaDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-4204-7670
Jennifer E NormanDivision of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, California.ORCID 0000-0002-6903-6031
Bamba EnkhmaaDivision of Endocrinology, Department of Internal Medicine, University of California, Davis, California.ORCID 0000-0002-1429-6864
Madelynn TuckerDepartment of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California Davis, Sacramento, California.
Brian J BennettObesity and Metabolism Research Unit, Western Human Nutrition Research Center, USDA ARS, Davis, California.ORCID 0000-0002-0766-3195
Leila R ZelnickDivision of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington.ORCID 0000-0002-8461-5111
Sili FanDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, California.
Lars F BerglundDepartment of Internal Medicine, University of California, Davis, California.ORCID 0000-0001-6705-1791
Talat Alp IkizlerDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-5717-4218
Ian H de BoerDivision of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington.ORCID 0000-0003-1571-7592
Bethany P CummingsDepartment of Surgery, Center for Alimentary and Metabolic Sciences, School of Medicine, University of California Davis, Sacramento, California.
Baback RoshanravanDivision of Nephrology, Department of Internal Medicine, University of California, Davis, California.ORCID 0000-0003-1320-0442
Funding
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Tomas Vaisar · 1986 to 2026
$41.4M
NRSA Training CoreTL1DK139565 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILIP A BEACHY, Chi-yuan Hsu · 2023 to 2026
$5.1M
Professional Development CoreU2CDK133488 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elaine Ku, Kathleen M Sakamoto · 2023 to 2026
$4.1M
Role of Mitochondrial Dysfunction in the Response to Exercise in Patients with Advanced Kidney DiseaseR01DK125794 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAMBOA, JORGE LUIS, IKIZLER, TALAT ALP · 2021 to 2025
$3.3M
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney diseaseR01DK129793 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ROSHANRAVAN, BABACK · 2021 to 2025
$3.2M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
Integration of Nutritional Metabolomics with Bioenergetics in Cystic FibrosisK01DK102851 · NIDDK · EMORY UNIVERSITY · PI ALVAREZ, JESSICA ALEJANDRA · 2014 to 2018
$614k
Defining alpha-cell proglucagon processing for type 2 diabetes treatmentR56DK124853 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CUMMINGS, BETHANY PAIGE · 2020 to 2020
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD. · full record | OpenQuestion